Assenagon Asset Management S.A. Raises Holdings in Establishment Labs Holdings Inc. $ESTA

Assenagon Asset Management S.A. raised its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 59.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,876 shares of the company’s stock after purchasing an additional 43,164 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Establishment Labs were worth $8,445,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Quarry LP acquired a new stake in shares of Establishment Labs in the third quarter worth $34,000. State of Wyoming acquired a new position in shares of Establishment Labs during the 3rd quarter valued at $71,000. Osaic Holdings Inc. boosted its position in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. PharVision Advisers LLC purchased a new stake in shares of Establishment Labs in the third quarter worth about $203,000. Finally, Brian Low Financial Group LLC acquired a new stake in Establishment Labs in the third quarter valued at approximately $223,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

ESTA stock opened at $55.31 on Friday. Establishment Labs Holdings Inc. has a 1 year low of $26.56 and a 1 year high of $83.31. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -31.79 and a beta of 0.91. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The stock’s fifty day moving average is $68.98 and its two-hundred day moving average is $61.88.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company’s quarterly revenue was up 45.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.19) earnings per share. On average, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ESTA shares. Canaccord Genuity Group raised their target price on Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Needham & Company LLC raised their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Stephens boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. BTIG Research upped their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Finally, JPMorgan Chase & Co. lifted their price target on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average target price of $86.86.

Insider Transactions at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 33,925 shares of the firm’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the transaction, the director directly owned 1,223,579 shares of the company’s stock, valued at approximately $73,891,935.81. This trade represents a 2.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.09% of the stock is owned by company insiders.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.